Recommendations regarding the response assessment in CLL patients
| Diagnostic test . | General practice . | Clinical trial . |
|---|---|---|
| History, physical examination | Always | Always |
| CBC and differential count | Always | Always |
| Marrow aspirate and biopsy | At cytopenia of uncertain cause | At CR or cytopenia of uncertain cause |
| Assessment for minimal residual disease | NGI | Desirable |
| Ultrasound of the abdomen* | Possible, if previously abnormal | NGI |
| CT scans of chest, abdomen, and pelvis | NGI | Recommended if previously abnormal and otherwise with a CR and PR |
| Diagnostic test . | General practice . | Clinical trial . |
|---|---|---|
| History, physical examination | Always | Always |
| CBC and differential count | Always | Always |
| Marrow aspirate and biopsy | At cytopenia of uncertain cause | At CR or cytopenia of uncertain cause |
| Assessment for minimal residual disease | NGI | Desirable |
| Ultrasound of the abdomen* | Possible, if previously abnormal | NGI |
| CT scans of chest, abdomen, and pelvis | NGI | Recommended if previously abnormal and otherwise with a CR and PR |
For a detailed description of these parameters, see section 5. General practice is defined as the use of accepted treatment options for a CLL patient not enrolled on a clinical trial.
Used in some countries to monitor lymphadenopathy and organomegaly.